Operational Controls to Mitigate SARS-CoV-2 Challenge to Virus Control Framework in Industrial GMP Manufacturing Facilities Webinar

Complimentary
Learning Level: Intermediate

The SARS-CoV-2 worldwide pandemic has presented a significant challenge to business continuity for pharmaceutical manufacturing. It has led to Industry re-assessing the virus control framework, and in particular, any challenges that this may present to the mitigations currently in place. This presentation will focus on the SARS-CoV-2 situation and factors to be assessed in a GMP Biopharmaceutical manufacturing facility and whether they present a secure virus mitigation strategy to protect the product from contamination from this and other viruses.

  1. The factors involved in the virus control framework for a Biopharmaceutical manufacturing facility with reference to ICH Q5A. 
  2. The planning activities required in order to prepare for a novel virus challenge to manufacturing facilities. 
  3. Ongoing virus risk management and mitigations. 
Risk Based Approach to mitigate SARS – COV -2

Download Presentation


Speaker

Anne Stokes, PhD
Director TSE and Virus Control
GlaxoSmithKline
Thomas B. Hartman
President and CEO
ISPE

Copyright Disclaimer

This copyright notice applies to all proprietary pages, images, text, programs, and other material available throughout this Internet site (collectively, this “Publication”). All materials posted on the website are subject to copyrights owned by the International Society for Pharmaceutical Engineering (“ISPE”) and other individuals or entities. Any reproduction, retransmission or republication of all or part of any documents found on this site is expressly prohibited, unless ISPE or the copyright owner of the material has expressly granted its prior written consent to reproduce, retransmit or republish the material. All other rights reserved. View entire copyright policy.

youtube
Subscribe to your ISPE YouTube Channel
& Click the bell for notifications.

View All Videos